Masatoshi Ishigami

7.3k total citations · 1 hit paper
278 papers, 4.7k citations indexed

About

Masatoshi Ishigami is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Masatoshi Ishigami has authored 278 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Epidemiology, 136 papers in Hepatology and 90 papers in Surgery. Recurrent topics in Masatoshi Ishigami's work include Liver Disease Diagnosis and Treatment (109 papers), Hepatitis C virus research (70 papers) and Pancreatic and Hepatic Oncology Research (52 papers). Masatoshi Ishigami is often cited by papers focused on Liver Disease Diagnosis and Treatment (109 papers), Hepatitis C virus research (70 papers) and Pancreatic and Hepatic Oncology Research (52 papers). Masatoshi Ishigami collaborates with scholars based in Japan, United States and South Korea. Masatoshi Ishigami's co-authors include Hidemi Goto, Yoshiki Hirooka, Takashi Honda, Yoshiaki Katano, Kazuhiko Hayashi, Yoji Ishizu, Teiji Kuzuya, Eizaburo Ohno, Hiroki Kawashima and Akihiro Ito and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Masatoshi Ishigami

268 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

2020 681 citations Masatoshi Ishigami, Hidenori Toyoda et al. profile →

Peers

Countries citing papers authored by Masatoshi Ishigami

Since Specialization

Citations

This map shows the geographic impact of Masatoshi Ishigami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masatoshi Ishigami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masatoshi Ishigami more than expected).

Fields of papers citing papers by Masatoshi Ishigami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masatoshi Ishigami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masatoshi Ishigami. The network helps show where Masatoshi Ishigami may publish in the future.

Co-authorship network of co-authors of Masatoshi Ishigami

This figure shows the co-authorship network connecting the top 25 collaborators of Masatoshi Ishigami. A scholar is included among the top collaborators of Masatoshi Ishigami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masatoshi Ishigami. Masatoshi Ishigami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma	Cancers	Kenta Yamamoto, Takashi Honda et al.	2
2	Distinct features of two lipid droplets types in cell nuclei from patients with liver diseases	Scientific Reports	Norihiro Imai, Yuki Ohsaki et al.	8
3	A new criterion including the aspartate aminotransferase‐to‐platelet ratio index and liver and spleen stiffness to rule out varices needing treatment in children with biliary atresia: Modification of the Baveno VII criteria	Hepatology Research	Shinya Yokoyama, Yoji Ishizu et al.	2
4	Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot study	Alimentary Pharmacology & Therapeutics	Masanao Nakamura, Takashi Honda et al.	22
5	Clustering using unsupervised machine learning to stratify the risk of immune‐related liver injury	Journal of Gastroenterology and Hepatology	Takafumi Yamamoto, Takanori Ito et al.	8
6	Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan	BMC Gastroenterology	Tsunaki Sawada, Takeshi Yamamura et al.	19
7	An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	Hepatology Research	Yoji Ishizu, Yukio Ando et al.	5
8	Comparison of an Inside Stent and a Fully Covered Self-Expandable Metallic Stent as Preoperative Biliary Drainage for Patients with Resectable Perihilar Cholangiocarcinoma	Canadian Journal of Gastroenterology and Hepatology	Hiroshi Mori, Hiroki Kawashima et al.	5
9	Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma	Digestive Diseases	Kenta Yamamoto, Takashi Honda et al.	7
10	Measurement of fasting breath hydrogen concentration as a simple diagnostic method for pancreatic exocrine insufficiency	BMC Gastroenterology	Hiroki Kawashima, Eizaburo Ohno et al.	4
11	Revisiting the indications for liver transplantation in cirrhotic patients considering the long‐term outcomes of cirrhotic patients	Journal of Hepato-Biliary-Pancreatic Sciences	Masatoshi Ishigami, Takashi Honda et al.	5
12	The microbiome can predict mucosal healing in small intestine in patients with Crohn’s disease	Journal of Gastroenterology	Masanao Nakamura, Takeshi Yamamura et al.	17
13	Lewis score on capsule endoscopy can predict the prognosis in patients with small bowel lesions of Crohn's disease	Journal of Gastroenterology and Hepatology	Masanao Nakamura, Takeshi Yamamura et al.	12
14	Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma	Hepatology Research	Teiji Kuzuya, Masatoshi Ishigami et al.	25
15	Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment	Oncology	Teiji Kuzuya, Masatoshi Ishigami et al.	14
16	Multifaceted Therapeutic Benefits of Factors Derived From Dental Pulp Stem Cells for Mouse Liver Fibrosis	Stem Cells Translational Medicine	Masatoshi Ishigami, Yoshihiro Matsushita et al.	53
17	Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma	Oncology	Teiji Kuzuya, Masatoshi Ishigami et al.	9
18	Copper Accumulates in Hemosiderins in Livers of Patients with Iron Overload Syndromes	Journal of Clinical and Translational Hepatology	Masatoshi Ishigami, Kazuhiko Hayashi et al.	8
19	Effect of peginterferon alfa‐2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C	Journal of Gastroenterology and Hepatology	Takashi Honda, Masatoshi Ishigami et al.	7
20	Association of interleukin 28 B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness	Journal of Gastroenterology and Hepatology	Kazuhiko Hayashi, Yoshiaki Katano et al.	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact